The sales of Lincoln Pharmaceuticals Ltd for the quarter ended September 2003 (Q2) has shot up to Rs.10.13 crore from Rs.8.71 crore during the previous period and the gross profit has increased to Rs.1.08 crore.
The net profit has gone up to Rs.0.97 crore reflecting a healthy growth of 18 per cent on the bottom line. The results were announced by the company at its board meeting held on October 6, 2003.
The company has an equity capital of Rs.5.90 crore with about 60.75 per cent stake belonging to the promoters. For the first half of the current year ending September 2003, the figures stand as follows:
Sale Rs.21.15 crore (previous half Rs.17.32 crore), PBDT Rs.2.01 crores (1.77) and net profit Rs.179 crores (1.55). Audited results for the year 2002-03 show a sales turnover of Rs.33.56 crore a PBDT of Rs.2.19 and a net profit of Rs.1.44 crore. The company has crossed the entire previous years' net profit in the current first half itself.
Lincoln Pharma also undertakes contract manufacturing on behalf of reputed multinational pharma companies and other reputed Indian pharma companies. Lincoln has recently launched an antibiotic Gatlink at affordable prices for respiratory diseases infected patients.
Lincoln expects to achieve a turnover of Rs. 45 crore in the current year.